View Older Stories View More Recent Stories

Feb 8, 2023 09:30AM Enanta Pharmaceuticals (ENTA) PT Raised to $68 at H.C. Wainwright

Jan 4, 2023 06:13AM Vera Therapeutics (VERA) PT Lowered to $15 at H.C. Wainwright, 'a clear sign that the results fell short of management's own expectations'

Dec 30, 2022 06:04AM H.C. Wainwright Assumes Ultragenyx Pharma (RARE) at Buy, PT $82, 'Steep Discount Heading Into a Catalyst-Rich 2023'

Dec 19, 2022 06:04AM H.C. Wainwright Starts Acurx Pharmaceuticals inc. (ACXP) at Buy, PT $14

Dec 15, 2022 12:04PM H.C. Wainwright Downgrades Axcella Health Inc. (AXLA) to Neutral

Nov 16, 2022 11:10AM Intercept Pharmaceuticals (ICPT) PT Lowered to $14 at H.C. Wainwright

Oct 26, 2022 08:04AM Unicycive to Showcase Pipeline of Innovative Product Candidates at American Society of Nephrology’s Kidney Week 2022

Oct 14, 2022 11:00AM Travere Therapeutics (TVTX) PT Lowered to $36 at H.C. Wainwright

Oct 12, 2022 12:08PM Albireo Pharma (ALBO) PT Raised to $68 at H.C. Wainwright

Oct 3, 2022 06:11AM Axcella Health Inc. (AXLA) PT Raised to $10 at H.C. Wainwright

Sep 20, 2022 11:19AM H.C. Wainwright Reiterates Buy Rating on Aurinia Pharma (AUPH) as EU approval of LUPKYNIS triggers a $30M milestone payment

Aug 17, 2022 06:13AM H.C. Wainwright Reiterates Buy Rating, $27 Price Target on 89bio Inc. (ETNB)

Jul 19, 2022 06:11AM H.C. Wainwright Reiterates Buy Rating, $9 Price Target on Unicycive Therapeutics (UNCY)

Jul 11, 2022 09:01AM Pliant Therapeutics (PLRX) Shares Surge, H.C. Wainwright Comments on PLN-74809, Keeps $45 PT

Jul 7, 2022 06:12AM H.C. Wainwright Reiterates Buy Rating, $80 Price Target on Albireo Pharma (ALBO)

Jul 1, 2022 06:07AM H.C. Wainwright Reiterates Buy Rating, $1.25 Price Target on Akebia Therapeutics (AKBA)

Jun 22, 2022 06:08AM H.C. Wainwright Reiterates Buy Rating, $20 on Paratek Pharmaceuticals (PRTK) on NUZYRA's Fast-Track Designation

Jun 8, 2022 06:04AM UPDATE: H.C. Wainwright Starts Unicycive Therapeutics (UNCY) at Buy

May 18, 2022 01:53PM DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference

May 18, 2022 06:11AM H.C. Wainwright Reiterates Maintains Galmed Pharmaceuticals (GLMD) at Neutral on Aramchol Uncertainties

May 4, 2022 06:16AM H.C. Wainwright Reiterates Buy Rating, $45 Price Target on Pliant Therapeutics (PLRX)

May 3, 2022 06:08AM UPDATE: H.C. Wainwright Downgrades Galmed Pharmaceuticals (GLMD) to Neutral

May 2, 2022 06:05AM UPDATE: H.C. Wainwright Starts Vera Therapeutics (VERA) at Buy

Apr 8, 2022 06:11AM H.C. Wainwright Reiterates Neutral Rating, $2 PT on Akebia Therapeutics (AKBA)

Apr 5, 2022 06:12AM H.C. Wainwright Reiterates Buy Rating, $12 PT on CymaBay Therapeutic (CBAY)

Mar 31, 2022 07:11AM UPDATE: H.C. Wainwright Downgrades Akebia Therapeutics (AKBA) to Neutral

Mar 30, 2022 06:21AM H.C. Wainwright Reiterates Neutral Rating on AcelRx Pharmaceuticals (ACRX)

Mar 29, 2022 11:06AM H.C. Wainwright Reiterates Buy Rating on Albireo Pharma (ALBO), "We Remain Highly Confident in Bylvay's Likelihood of Success"

Mar 14, 2022 06:18AM Arbutus Biopharma (ABUS) PT Raised to $8.50 at H.C. Wainwright

Mar 14, 2022 06:13AM UPDATE: H.C. Wainwright Downgrades AcelRx Pharmaceuticals (ACRX) to Neutral

Mar 9, 2022 06:10AM H.C. Wainwright Reiterates Buy Rating on Paratek Pharmaceuticals (PRTK), Cites Impressive Preclinical Results in MAC Lung Infections

Mar 4, 2022 06:15AM UPDATE: H.C. Wainwright Downgrades Entasis Therapeutics (ETTX) to Neutral

Mar 3, 2022 06:13AM H.C. Wainwright Reiterates Neutral Rating on Intercept Pharmaceuticals (ICPT)

Mar 1, 2022 11:56AM UPDATE: Arcturus Therapeutics (ARCT) PT Lowered to $25 at H.C. Wainwright

Mar 1, 2022 09:30AM Aurinia Pharmaceuticals (AUPH) PT Lowered to $33 at H.C. Wainwright

Feb 28, 2022 06:21AM H.C. Wainwright Reiterates Buy Rating on Akero Therapeutics (AKRO), HARMONY Trial Results Remain Key Catalyst

Feb 28, 2022 06:14AM UPDATE: H.C. Wainwright Starts Travere Therapeutics (TVTX) at Buy

Feb 23, 2022 10:35AM H.C. Wainwright Reiterates Buy Rating on Akebia Therapeutics (AKBA)

Feb 23, 2022 07:42AM H.C. Wainwright Reiterates Buy Rating on Albireo Pharma (ALBO), Estimates Peak Bylvay PFIC Sales of $446M

Feb 18, 2022 06:17AM Arcturus Therapeutics (ARCT) Maintained at Neutral by H.C. Wainwright, Waiting for Pivotal Data for Arcturus' COVID-19 Vaccine Approval

Feb 8, 2022 06:22AM No Significant Impact on Intercept (ICPT) from France Withdrawal, Focus Remains on Future Data - H. C. Wainwright

Jan 26, 2022 07:42AM Arcturus Therapeutics (ARCT) PT Lowered to $33 at H.C. Wainwright

Jan 12, 2022 06:21AM Strong Early Momentum for LIVMARLI Sets Stage for Active 2022 for Mirum Pharamceuticals (MIRM) - H.C. Wainwright

Jan 7, 2022 06:46AM Albireo Pharma (ALBO) Bylvay Launch Faster Than Anticipated, Raising Estimates - H.C. Wainwright

Dec 30, 2021 11:02AM No Negative in Madrigal Pharma's (MDGL) Topline Data Delay - H. C. Wainwright

Dec 20, 2021 06:12AM UPDATE: H.C. Wainwright Upgrades Genfit (GNFT) to Buy

Dec 20, 2021 06:10AM UPDATE: H.C. Wainwright Starts 89bio Inc. (ETNB) at Buy

Dec 16, 2021 11:00AM AcelRx Pharma's (ACRX) New Study Shows Multiple Advantages of DSUVIA Over Conventional Pain Management - H.C.Wainwright

Dec 8, 2021 12:07PM H.C. Wainwright Reiterates Buy Rating on Arbutus Biopharma (ABUS) Amid Progress on Pan-Coronavirus Treatment

Dec 3, 2021 06:11AM H.C. Wainwright Assumes Cidara Therapeutics (CDTX) at Buy

View More Recent Stories View Older Stories